News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
FDA Says GlaxoSmithKline Drug Promacta Fails to Control Bleeding
May 29, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON - An experimental drug from GlaxoSmithKline does not significantly lower bleeding in patients with a rare blood disorder, according to the Food and Drug Administration.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
GlaxoSmithKline
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Women’s health
Biotech Leaders, Investors Ask FDA to Maintain Access to Mifepristone
July 3, 2025
·
2 min read
·
Tristan Manalac
Legal
Court Suspends Mass Layoffs at HHS, Rules Staff Cuts Likely Unlawful
July 2, 2025
·
2 min read
·
Tristan Manalac
Government
RFK Jr. Eyes Changes to Vaccine Injury Compensation Program
July 2, 2025
·
2 min read
·
Tristan Manalac
Regulatory
FDA Mulls ‘Regulatory Action’ on Argenx’s Vyvgart Hytrulo Over Severe Safety Concerns
July 2, 2025
·
2 min read
·
Tristan Manalac